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Abstract Many recent research studies have proposed stem
cell therapy as a treatment for cancer, spinal cord injuries,
brain damage, cardiovascular disease, and other conditions.
Some of these experimental therapies have been tested in
small animals and, in rare cases, in humans. Medical
researchers anticipate extensive clinical applications of
stem cell therapy in the future. The lack of basic knowledge
concerning basic stem cell biology-survival, migration,
differentiation, integration in a real time manner when
transplanted into damaged CNS remains an absolute
bottleneck for attempt to design stem cell therapies for
CNS diseases. A major challenge to the development of
clinical applied stem cell therapy in medical practice
remains the lack of efficient stem cell tracking methods.
As a result, the fate of the vast majority of stem cells
transplanted in the human central nervous system (CNS),
particularly in the detrimental effects, remains unknown.
The paucity of knowledge concerning basic stem cell
biology—survival, migration, differentiation, integration in
real-time when transplanted into damaged CNS remains a
bottleneck in the attempt to design stem cell therapies for
CNS diseases. Even though excellent histological techni-
ques remain as the gold standard, no good in vivo
techniques are currently available to assess the transplanted
graft for migration, differentiation, or survival. To address
these issues, herein we propose strategies to investigate the
lineage fate determination of derived human embryonic
stem cells (hESC) transplanted in vivo into the CNS. Here,
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we describe a comprehensive biological Global Positioning
System (bGPS) to track transplanted stem cells. But, first,
we review, four currently used standard methods for
tracking stem cells in vivo: magnetic resonance imaging
(MRI), bioluminescence imaging (BLI), positron emission
tomography (PET) imaging and fluorescence imaging (FLI)
with quantum dots. We summarize these modalities and
propose criteria that can be employed to rank the practical
usefulness for specific applications. Based on the results of
this review, we argue that additional qualities are still
needed to advance these modalities toward clinical appli-
cations. We then discuss an ideal procedure for labeling and
tracking stem cells in vivo, finally, we present a novel
imaging system based on our experiments.
Keywords Stem cells . Tracking system . Biological Global
Positioning System (bGPS)
Introduction
Stem cell therapies hold promise for the treatment of
various human diseases. Emerging data indicate that trans-
planted stem cells have the potential to be beneficial or
detrimental to patients [1–3]. Future clinical trials will
require determining the location and number of transplanted
stem cells in vivo, over a life time [4, 5]. It is very difficult
to track small numbers of cells in the body with current
technologies. Current imaging modalities available for in
vivo tracking of the biological fate of stem cells have been
proposed, including Magnetic Resonance Imaging (MRI),
Positron Emission Tomography (PET), Bioluminescence
Imaging (BLI), and Fluorescence Imaging (FLI) with
quantum dots (QD). None of these modalities, however,
are optimal. Here, we discuss the advantages and disadvan-
tages of current imaging technologies with respect to stem
cell tracking applications, define the characteristics of an
ideal imaging technology, and propose a new system
specifically for stem cell imaging during clinical trials.
Magnetic Resonance Imaging (MRI)
MRI is a widely used medical imaging technique in which
magnetic fields are used to detect the nuclear spin of
molecules [6]. MRI is the most readily accessible tracking
method. Under proper conditions, it is safe and reliable as
well as available in most hospitals. MRI has been success-
fully to detect and track stem cell migration, particularly in
cardiac, liver, [7–11] and brain disease models [12–23]. MRI
techniques have been utilized to detect the presence and/or
migration of transplanted stem cells in various animal
models [24]. Surprisingly, MRI can detect a single hepatocyte
grafted into a transplanted liver upon perfusion of the
primary hepatocytes with double-labeled, green fluorescent
1.63-microm iron oxide particles and red fluorescent
endosomal labeling dye, injected into the spleens of recipient
mice [10]. The ability to detect single transplanted cells in
vivo raises the interest in monitoring stem cell behavior for
early detection of transplanted stem cell initiated tumorigen-
esis (teratoma formation), which may result from the use of
stem cells outside of their “therapeutic window” [25].
The benefits of MRI include high resolution and 3-D
anatomical imaging capability. Drawbacks include low
sensitivity and difficulty in quantifying a labeled cell
population [26]. MRI generally has lower sensitivity, but
produces high soft-tissue contrast and provides spectro-
scopic information and functional MRI (fMRI) [27, 28].
However, dilution of intracellular markers occur with each cell
division, and false signals may occur due to shedding and
subsequent sequestration of iron particles [29].
There are two general categories of cellular MRI
markers, T1 and T2/T2*, with T2 contrast being more
commonly employed in MR imaging. Gadolinium (Gd3+)
contrast enhanced imaging is employed for T1 systems.
Apart from Gd, Manganese is also a T1 agent [30, 31]. T2
contrast agents include superparamagnetic iron oxides
(SPIO) [32], ultrasmall superparamagnetic iron oxides
(USPIO), and magnetodendrimers [27], micron sized
particles of iron oxide (MPIOs) [33]. These magnetic
markers are sequestered into stem cells. They may exhibit
long-term health problems due to endocytosis of magnetic
particles with CNS (Fig. 1). The clinically transferable
properties of superparamagnetic iron oxide nanoparticles
(SPIO) requires modification in MR for tracking stem cells
in living organisms [4]. MRI can be used to track cells
labeled with iron particles in damaged tissues for at least
16 weeks after injection and to guide tissue sectioning by
accurately identifying regions of cell engraftment. The
magnetic properties of iron-labeled donor cells can be used
for their subsequent isolation from host tissue to enable
further characterization [34].
Bioluminescence Imaging (BLI)
Bioluminescence imaging is a technique in which a charged-
coupled device camera detects light emitted from the substrate
of the enzyme luciferase. The luciferase gene is incorporated
into for example a lentiviral vector, and this vector transfects
the luciferase indicator transgene into the defined stem cell
populations. Firefly luciferase, in the presence of substrate D-
luciferin, oxygen and ATP, emits light at about 560 nm [35]
(Fig. 2). Bioluminescence imaging is safe, permitting the
repeated tracking of small numbers of labeled cells.
Bioluminescence imaging is typically not as sensitive to a
small number of cells as MRI or PET. This technique has
been little used in humans due to concern about immuno-
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genicity of the proteins and products involved. In addition,
human clinical applications are limited because of the high
absorbance and scattering of luminescence in living tissue.
As such, BLI is likely to be limited to its current use in
imaging transfected stem cells in small animals.
Positron Emission Tomography (PET)
PET uses positron emitting radioisotopes as probes for
imaging cells in vivo [36, 37]. The decay of a radioisotope
produces two high-energy (511 keV) gamma photons that
travel in two opposite directions, which are collected and
verified by a ring of scintillating crystals. PET scanners can
be used in conjunction with CT scanners to produce more
detailed, fused, 3-D anatomical images [38]. To date, most
clinical PET-CT studies have used radioactive metals such
as 18F-fluoro-2-deoxyglucose (18FDG) and 64Cu, as imaging
markers [39, 40]. These markers need a chelator such as
PTSM to label cells [41–43], and have been used to track
mesenchymal stem cells [38]. Alternatively, the reporter gene
method, using herpes simplex virus type 1 thymidine kinase
(HSV1-tk), is a stable labeling method (Fig. 2) [44]. However,
the latter method poses a dilemma because it has the potential
to alter the genetic properties of labeled stem cells. Although
the value of PET lies in its high-sensitivity tracking of
biomarkers in vivo, it lacks the ability to resolve morphology.
Using PET and CT fused images, Love et al. were able
to locate and detect as few as 10,000 mesenchymal stem
cells (MSC) for over a two-month period in mice [38].
Potential disadvantages of PET include repeated injection
of radioactive materials into an organism with the potential
for radioactive damage to normal tissue associated with
cumulative radiation and exposure of surrounding tissues
[26]. Additionally, most currently available radiotracers
have short half lives which makes them less suitable for
long-term tracking. Imaging by positron emission tomog-
raphy may generate stem-cell specific signals only if the
marker is restricted to the stem cell and is the sole source
producing a signal of radioactive decay. However, PET
detects only the radioisotope. If the radiometals is released
from the stem cell, the signal will reflect the location of
isotope but not the stem cell. In fact, we know that
transchelation is common.
Engineering cells with receptors for imaging is unlikely
to find its application in human patients. Furthermore, PET
imaging requires quite a bit of post-processing of images to
get an image and it is therefore unlikely to be of great use
immediately after implantation to track and guide the
injection of stem cells.
Fig. 2 Reporter gene methods appear to be the most effective way to
stably integrate markers into cells for bioluminescence imaging and
PET imaging. By inserting a gene into the cell, the marker becomes
stem-cell specific and will not transfer to surrounding non-stem cells.
The use of a reporter gene allows for serial transgene expression along
with key cellular properties (differentiation, proliferation and cell
viability). This tracking strategy can be integrated to track stem cells
with other modalities (BLI, PET, and MPM)
Fig. 1 Direct label of stem cells
with markers. Left: by the process
of phagocytosis of SPIO (usually
coated with dextran). Middle:
USPIO are taken in by pinocy-
tosis [47]. Right: for cells without
phagocytic ability, receptor-
mediated endocytosis is used to
facilitate labeling
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Quantum Dots (QDots or QD)
Quantum dots (QDots or QD) represent one of several types
of fluorescent imaging agents. (QDots are semiconductor
particles with physical properties that enable them to emit
fluorescent light from 525 to 800 nm (Fig. 3). Quantum dots
consist of an inorganic core, a shell of metal and an outer
organic coating with a total diameter of 2–10 nm [45].
Quantum dots are capable of entering stem cells through
passive loading, receptor-mediated endocytosis or transfec-
tion [46]. Passive loading has been found to be the most
effective method because it is efficient at labeling, limiting
damage to surrounding stem cells. Quantum dots are
capable of multiplex imaging [47], single quantum dot
tracking [48], and 3-D imaging reconstruction [46].
Quantum dots represent a fairly new advance for
tracking stem cells. However, light scattering for quantum
dots limits the applicability of this approach, especially to
the brain in humans. This scattering property makes it very
difficult for use in 3D localization or quantitative estima-
tion of cell survival, which is clearly desired properties in
vivo imaging. The long-term biological health effects are
unknown, and the method has not yet been used in vivo to
track stem cells in animals larger than mice.
Multimodal Imaging
Multimodal imaging is becoming more popular because
of its improved sensitivity, high resolution, and morpho-
logical visualization. More than a decade ago, Simon
Cherry at the University of California, Davis, began
working on small animal imaging system combining
modalities with crucial qualities: MRI, with its excellent
spatial resolution and high-contrast morphologic imaging
of soft tissues; and PET, which can track the distribution
of biologically targeted radiotracers with high sensitivity,
but lacks anatomic context and spatial resolution.
Physical constraints (i.e., no metal can get inside the
MRI magnet) have frustrated these efforts. Cherry’s
group has recently revolutionized the identification of
cancer biomarkers by creating an MRI-compatible PET
scanner, allowing data from both modalities to be
acquired simultaneously [49]. Judenhofer and colleagues
reported that they have developed a three-dimensional
animal PET scanner that is built into a 7-T MRI for a
combined molecular imaging system [50], simultaneously
acquiring functional and morphological PET-MRI data
from living mice. Such a PET-MRI provides a powerful
tool for studying biology and pathology in preclinical
research and has great potential for clinical applications.
Shen et al. combined MRI and PET methods to create
multimodal imaging for infarcted myocardium in rats
[51]. This technique is integrated for coregistration of PET
(with higher sensivitity) or SPECT images with MRI (with
3-D anatomical details of MR scanning) and allows
mapping of the location and distribution of stem cells on
detailed myocardium structures. A new framework for
how whole body imaging using different techniques can
be integrated needs to be proposed and tested for stem
cell tracking.
Whole body imaging using different techniques has been
tested in small animals for feasibility. I (Intravenous)
injections of the 111In-oxine-labeled human embryonic stem
(ES) cell-derived neural progenitors and rat hippocampal
progenitors accumulated primarily into internal organs,
instead of in the targeted brain [52] while intra-arterial
injection of the labeled stem cells showed a weak signal in
the ischemic hemisphere detected using SPECT/CT device.
The limit of detection sensitivity of SPECT/CT device was
approximately 1,000 111In-oxine-labeled cells.
Requirements for Clinical Applications
Definition of a Biological Global Positioning System
(bGPS) for tracking stem cells. The ability to observe
targeted stem cell behaviors using a system capable of
scanning for transplanted stem cells throughout the whole
body, at any given time is essential to determining whether
or not transplanted stem cells in any given clinical
intervention is beneficial or harmful in vivo. An advanced
bGPS system could be employed to record viability,
Fig. 3 Quantum dots (QD) are directly loaded into stem cells and
used in multplex imaging. Multiplex Imaging (Stacked Image) based
on the energy absorbed is different. Some QDs absorb less energy
than others because QDs can produce different light levels at the same
excitation wavelength QD 525, 565, 605, 655, 705, and 800 were used
to label stem cells. QDs were excited by the same wavelength, which
is why longer wavelengths are brighter [47]
320 Stem Cell Rev and Rep (2010) 6:317–333
differentiation state and the functionality of targeted stem
cells in vivo. Specifically, bGPS can be defined as a unit
device to locate and record at regular intervals the precise
location of a transplanted stem cell in tissue to which it has
migrated within the body. Additionally, a bGPS could be
designed to record and track the differentiation state,
physiological or pathological state, direction and movement
of a transplanted stem cell through the body during the time
in which it remains in vivo. The work flow for labeling and
tracking stem cells is described in Fig. 4. Critical elements
in bGPS include:
(1) Sensitivity for single cell detection.
(2) Real-time positioning: Ideally, targeted stem cells
could be monitored as they travel throughout the body
over any given time period in order.
(3) An inducible system: Signal retrieval under the control
of an inducing mechanism to minimize the impact of
intervention on the host.
(4) Retractable: Ability to inactivate stem cells should
effects prove deleterious.
(5) Targeted and durable: Label detectable for the life-
time of the cell and not transferable to host cells.
(6) Monitoring cell fate: Ability to track cell viability,
proliferation, and differentiation state in vivo. More
specifically, monitoring physiological changes in the stem
cells, e.g., the growth rate (size of the cell), the proliferation
rate (the number of the cell), and the differentiation state
(the functional transformation). i.e., the label should last
for the life time of the stem cell in vivo.
(7) Compliant with the FDA GMP guidelines for clinical
applications.
Fig. 4 Multimodality of imaging can be applied for tracking stem cell
behavior. A work flow chart for labeling cells and introducing labeled
cells into the human body include: (1) Cell is labeled using a marker
for magnetic resonance imaging (MRI), bioluminescence imaging
(BLI), positron emission tomography (PET) or fluorescence imaging
(FLI). (2) Cells are cultured in vitro and ex vivo (i.e., OTS), and then
(3) Injected intravenously into the human body. (4) Stem cells are then
tracked in the body with a camera or scanner
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An ideal procedure for labeling and tracking stem cells
in vivo is illustrated (Fig. 4). Optimal qualities for cell
tracking strategies were proposed by Fragioni [26]. These
include biocompatibility, nontoxicity, quantification, no
genetic modification, no perturbation of stem cells, and
noninvasive imaging. Additional qualities were posited,
including (1) specificity of stem cell labeling, (2) continu-
ous in vivo tracking, (3) imaging in a greater depth, and (4)
specificity of stem cell imaging. These four requirements
are addressed respectively with four currently used tracking
methods (Table 1).
Specificity of Stem Cell Labeling
The confusion between specificity and sensitivity can be
clarified as follows: Specificity reflects the ability to
differentiate transplanted cells from a host cell or an
artifact. In this application, sensitivity describes the
minimum number of labelled cells necessary for detection;
ideally this would be one cell. For example, MRI is
sensitive enough to detect transplanted cells (even a single
one), but not specific enough to distinguish it from ferritin
deposits in host cells. For example, the blooming effect of
iron oxide particles poses a potential obstacle to locating
cells by diffusing a signal across a much larger area than
where a transplanted stem cell is actually located. There is a
thorough study on fluorine imaging by MRI to selectively
and quantitatively detect transplanted cells and avoid many
of the artifact traps associated with ferritin labeling [53].
Specific labeling of targeted stem cells could be
accomplished through genetically labeling using a reporter
gene (Fig. 2). This reporter gene allows for detection of
serial transgene expression in conjunction with key cellular
properties (differentiation, proliferation and cell viability)
[54–57]. This tracking strategy can be used with other
modalities including PET, BLI, and MPM. Labeling
specificity is an important requirement for tracking stem
cells because it ensures that the label is present only in the
stem cells of interest. Furthermore, the label should not
interact with or transfer from stem cells to surrounding non-
stem cells. Stem cells would ideally retain the label for life
in order to maintain specific targeting in vivo. After a
labeled cell dies, the label should spontaneously dissipate
or be eliminated to prevent re-uptake by surrounding non-
stem cells and to indicate that the labeled stem cell has been
cleared.
Luciferase, used for bioluminescence imaging, remains
specific to transduced stem cells because the marker gene is
incorporated into the DNA of the labeled stem cell. Although
the marker is retained within the cell, bioluminescence
imaging can still be distorted because the surrounding living
tissue absorbs and scatters the light given off by the luciferase
marker [26].
The magnetic markers used in MRI are not neccessarily
specific to stem cells. Iron oxide nanoparticles can
potentially transfer from stem cells to non-stem cells, such
as macrophages. Moreover, these iron particles may shed or
spill from stem cells into the surrounding living tissue [6,
26, 29]. To address these issues, Modo et al. (2002)
established that the Gd particles remained inside labeled
cells in a co-culture system [58] and the uptake of USPIO
in macrophages was demonstrated in an in vitro system
[59].
Depending on the mechanism used to insert the marker
into the stem cell, positron emission tomography may or
may not specifically detect only labeled stem cells. When a
radiotracer is directly loaded into a cell, the possibility
exists that non-stem cells will uptake the marker [1].
Alternatively, we can design an enzymatic conversion/
retention of radiotracers for stable incorporation of markers
into the stem cell, eliminating the possibility of transferring
markers from labeled stem cells to non-labeled cells.
Quantum dots might be used as markers but, in
comparison, are not stem cell-specific. While passive
loading of bare quantum dots into mesenchymal stem
cells provided a very effective method of delivery [46],
the dots demonstrated no specificity for stem cell binding,
and therefore, the possibility that quantum dots can spill
out of the labeled stem cells, resulting in a loss of
fluorescent signal. Quantum dots, however, do not appear
to be transferable from labeled stem cells to non-stem
cells. When QD-labeled human mesenchymal stem cells
BLI QD MRI PET
Specificity for stem cell labeling ● × × ●
Marker is nontoxic to stem cell ● ● ●a ●
Marker does not alter stem cell properties ● ● ● ●
Non-invasive tracking × ● ● ×
Continuous in vivo tracking for up to one month ● × ● ●
Tracked at >3 in depth from skin × × ● ●
Specificity for stem cell imaging ● ● × ●
Quantification capability ● × × ●
Table 1 Comparison of currently
used methods for tracking stem
cells
● Indicates that tracking method
fulfills this capability
× Indicates that tracking method
does not fulfill this capability
a There are reports to show that
the marker particles are toxic for
certain functions for stem cells
(see the text for details)
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were perfused in animals, adjacent cardiac cells failed to
take up the released quantum dots in vivo [46].
Marker is Nontoxic to Stem Cells
An essential requirement for cell labels is that they are not
toxic over time. Markers for bioluminescence labeling,
small doses of radiotracers for PET, and small amounts of
quantum dots have generally not shown to be toxic to
labeled cells. Still, Lin, et al. demonstrated for fluorescent
imaging that although quantum dots are generally nontoxic,
escalating concentrations (>20 nmol/L) of quantum dots
prove to be cytotoxic over time [47]. A recent study found
that commonly used iron oxide nanoparticles used for MR
imaging can have toxic effects on neuronal cells [48]. The
possibility that iron oxide nanoparticles can transfer from
labeled cells to neuronal cells poses a hindrance to clinical
applications of tracking stem cells through MR imaging.
Modo et al. (2008) followed Gd-labeled cells over one year
and found that although there was no in vitro effect, cells
labeled with Gd did not recover as they exerted deleterious
effects on repair [60]. Microscopy studies revealed lyso-
somal compartmentalization of iron particles in human
mesenchymal stem cells up to 14 days after labeling [61].
With subsequent loss of the compartmentalization of iron
oxide particles, resulting in release of iron oxides into the
adjacent environment clearly, clinical safety standards for
the application of labels remain to be defined.
Marker does not Alter Stem Cell Properties
While searching for ideal labeling strategies, it is essential
that imaging must not alter the behavior or fate of marked
stem cell populations. No major adverse effects of the four
imaging techniques have been shown to interfere with stem
cell life span or the ability to proliferate over the time
period observed [62–66]. Indeed, in vitro labeling of human
central nervous system stem cells with magnetic nano-
particles does not adversely affect survival, migration, and
differentiation or alter neuronal electrophysiological char-
acteristics [67]. Amazingly, these labeled human central
nervous system stem cells transplanted either to the
neonatal, the adult, or the injured rodent brain responded
to cues characteristic for the ambient microenvironment.
They survive long-term and differentiate in a site-specific
manner identical to that seen for transplants of unlabeled
cells. However, it was reported that a reporter gene is a
better marker for monitoring cell viability, whereas iron
particle labeling is a better marker for high-resolution
detection of cell location by MRI [68]. No significant
difference has been reported thus far in stem cell growth
and development when a marker is added to the cell [47].
Time-lapse microscopy successfully captured a moment of
dramatic change in chromosome positioning during the
transition between two differentiation stages of pluripotent
mouse ES cells [69]. These images following the epigenetic
markers showed unique nuclear organization in that
methylated centromeric heterochromatin coalesced to form
large clusters around the nucleoli. Upon differentiation, the
organization of these heterochromatin clusters changed
dramatically.
However, Kostrua et al. (2005) showed that using iron
oxide particles on mesenchymal cells impaired their ability
to differentiate into chrondrocytes [70, 71]. The inhibitory
effect of iron oxide compounds on stem cell differentiation
was a major issue in using labeled stem cells for infarcted
myocardium repair [11]. There is, however, no demonstra-
ble effect on stem cells originating from the CNS including
viability, proliferation, or multipotency [72]. Moreover, it is
becoming increasingly clear that one of the major effects of
stem cells (regardless of their niche of origin) is mediated
through the paracrine release of various cytokines or
growth factors [73–77]. It should be noted that probe
labeling of stem cells might alter this “paracrine effect.”
There is currently little data to prove or disprove the impact
of tracking agents on this important (in vivo) stem cell
“pro-healing” effect.
Non-invasive Tracking
Stem cell tracking in humans ideally should be non-
invasive. Both magnetic resonance scanners and fluores-
cent detectors for quantum dots can image stem cells
without procedures more invasive than stem cell injection.
Once these cells are labeled in vitro and transplanted into
the body, imaging for tracking the fate of these cells is
non-invasive.
Bioluminescent imaging and PET imaging require a
slightly more complicated process in which specific
substrates must also be injected in order to insert detectable
substrates into transplanted stem cells. These substrates,
when attached to the enzymes produced by labeled stem
cells, produce a signal which can be used to identify stem
cells in vivo. However, there have been concerns about the
effect of iron oxide compounds on stem cell differentiation,
a pivotal cell property [11].
Continuous Tracking In Vivo
In order to determine the accuracy and efficiency of stem
cell therapy in vivo, stem cells must be continuously
traceable from the time of injection to the time that they
reach a final destination. For example, stem cells should be
tracked for months at a time to monitor the long-term
engraftment and function of stem cells migrated to a
damaged region.
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However, most experiments tracking stem cells have
been conducted in small animals and last only days or
weeks. For clinical applications, stem cell labeling must
remain intact for months in order to monitor their
viability, proliferation, and integration into the targeted
host microenvironment.
J.M.W. Bulte et al. tracked magnetically labeled stem
cells traveling into the brain parenchyma for up to six
weeks, illustrating clinical potential of MRI [27]. However,
MRI technology still calls for improvement because each
cell division of a labeled cell reduces the concentration of
superparamagnetic iron oxide nanoparticles within prog-
eny cells. Such a progressive dilution of the cell marker
through cell division limits the capability of this method
for long-term tracking of stem cells. A study by Daldrup-
Link et al. demonstrated that with concentrations of less
than 20 nmol/ml, individually labeled cells cannot be
detected by MRI [78]. A threshold concentration must be
maintained in order for cells to be imaged by MRI. This
threshold limits the length of time that MRI can be used to
track stem cells in vivo.
Whereas the MRI technique can track magnetically
labeled cells for over a month, studies employing
bioluminescence imaging have successfully tracked cells
for up to three months [38]. Positron emission tomogra-
phy tracking has also been successfully employed for
over two months using the HSV1-tk reporter gene [38].
Transfecting the stem cell with reporter genes appears to
be a promising method for stable integration of a
marker into the target cell permitting longer periods of
tracking.
The capability for continuous tracking of quantum dots
in vivo has not been tested as rigorously as that for MRI,
bioluminescence imaging, or PET imaging. Although
current technology generally enables continuous in vivo
tracking in mice for only a few weeks [47], Rosen et al.
were able to identify stem cells within a canine heart
labeled by quantum dots 8 weeks after injection of
mesenchymal stem cells by ex vivo imaging of these cells
[46]. In order for quantum dots to be clinically useful,
larger test subjects must be used to determine the maximum
depth that emitted fluorescence can be reliably detected in
vivo and repeatedly.
Tracking and Depth
MRI, BLI, PET and QD techniques can successfully image
stem cells within small rodents. However, these same
tracking capabilities can not be currently translated into
imaging larger organisms, such as humans. Ideally, labeled
stem cells should be traceable at depths greater than 3 in.
from the skin in order to image internal organs, such as the
heart or the brain.
MRI and PET medical imaging routinely explore
internal regions of the human body, creating 3-D renditions
of the anatomy of interest. As such, MR and PET scanners
are advantageous for this desired characteristic of in-depth
detection.
A major impediment to the current use of bioluminescent
imaging in clinical applications is that luciferase and other
BLI markers can only be tracked to depths of 2–3 cm from
the skin [79]. While this does not pose a problem in
laboratory experiments with small animals, such superficial
imaging will not be practical with human patients. Imaging
of deeper regions, such as the human brain or heart, is
impractical with current BLI markers. There is a possibility
for deep tissue visualization with FLI and “stealth” near
infra-red fluorescent probes (See details in the later
sections).
Quantum dots may have great potential for tracking stem
cells in vivo at greater depths than conventional fluorescent
markers because of its increased intensity of light emission.
Ballou et al. have reported that fluorophore signals can be
detected deep from within the liver and bone marrow of a
mouse using whole-body imaging [80]. Additionally,
Larson et al. have been able to image quantum dot emission
signals in capillaries hundreds of millimeters deep in the
blood vessels from the skin of mice [81]. However,
experiments tracking stem cells in vivo in larger animals
must be conducted to determine the extent to which
quantum dot fluorescence can be tracked.
Specificity for Stem Cell Imaging
Specificity, the ability of an imaging method to accurately
discriminate between labeled stem cell and surrounding
non-specific signal noise, is a fundamental requirement for
stem cell tracking.
MRI has poor specificity because signal loss or gain
does not solely correlate with superparamagnetic iron oxide
(SPIO) MRI imaging contrast agent from a labeled cell.
With a negative contrast, it may become difficult to
distinguish between a signal loss from a labeled cell or
the innately low signal in tissue [51]. Additionally, Mani et
al. describes how cardiac imaging is difficult with MRI
because signal loss may not only be attributed to magnet-
ically labeled stem cells, but to motion, partial volume
averaging effects, and necrosis [29]. MRI is also not
sensitive enough to discriminate between a labeled stem
cell signal and products of ferritin deposition [29]. Positive
contrast, on the other hand, is not necessarily better than
negative contrast [82]. In neural imaging, hemorrhages,
extracellular SPIO or other iron-enriched brain regions can
be mistaken for a positive signal.
Bioluminescent markers are advantageous for produc-
ing stem cell-specific images. There is an inherently low
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background luminescence from tissue [35], making
bioluminescent markers easy to identify in vivo. In
comparison, negative or positive contrast signals from
MRI may be attributed to activity in the surrounding
tissue, which makes it difficult to distinguish stem cell
presence.
Quantum dots, like bioluminescent markers, have useful
qualities for producing stem cell-specific images. Their
fluorescent signals have very narrow emission spectra, so
the wavelength is specific to a particular-sized quantum dot.
In some studies, there was no background autofluorescence
to interfere with the quantum dots signal, and when there
was autofluorescence, programs can be used to eliminate it
from the image. Furthermore, their fluorescence is much
stronger than organic fluorophores [6].
Quantification Capability
Ideally, a linear relationship should exist between the
number of stem cells bearing a label and the generated
intensity or concentration of the emitted signal. This
relationship should follow a predictable course over the
lifespan of the label in order to derive absolute values.
Quantification is important to differentiate where the
majority of stem cells are located in comparison to where
minor populations of stem cells are found within an
organism. Daldrup-Link et al. found no significant correla-
tion between the number of labeled cells and MR imaging
data between 1×107 cells and 3×108 cells [78]. They
proved that quantification with MR imaging is limited for
stem cell tracking and a refinement is needed.
Quantification with bioluminescence imaging has been
performed. Togel et al. has found a linear relationship
between photon emission by the cell markers and the
number of stem cells [83]. PET is the only other tracking
method of the four in which there is a correlation between
signal intensity and population of labeled stem cells.
A Novel Practical Device Complementary to Establish
a GPS-like Tracking System for Tracking
Stem Cells In Vivo
An estimated 18,820 new cases of brain and other CNS
cancers will be diagnosed in the United States each year,
and more than 12,000 will die from the disease (data from
the US National Cancer Institute). Brain tumors are now the
leading cause of cancer-related deaths in children under age
15 [84]. Malignant brain tumors represent a major pediatric
and adult health care threat with long-term prognosis
remaining dismal [85]. New approaches to the treatment
of brain tumors are desperately needed. Public enthusiasm
has fueled interest in stem cell research as a promising
approach such that stem cell therapy has been regarded as
an eternal wonder medicine of “cure-it-all,” and novel
applications for stem cell therapy have been proposed for
the treatment of malignant gliomas as they “surround” the
invading tumor border while “chasing down” infiltrating
tumor cells [86, 87].
One major obstacle is to better understand how stem
cells access the brain tumor and move within it during
tumor initiation and progression. Aboody and colleagues
visualized and quantitatively analyzed the spatial distribu-
tion of tumor-tropic NSCs in a mouse model of orthotopic
glioma in order to predict the therapeutic efficacy of a
representative NSC-based glioma therapy [88]. However,
this single-color-dye-loaded and confocal microscopy-
based method is limited. Multiphoton excitation fluorescent
microscopy (MPM) is a laser-based technology that allows
subcellular resolution of native tissues in situ [89, 90]. As
compared with other in vivo imaging techniques, multiphoton
microscopy is uniquely capable of providing a window into
cellular and subcellular processes in the context of the intact,
functioning animal. In addition, the ability to collect multiple
colors of fluorescence from the same sample makes in vivo
microscopy uniquely capable of characterizing up to three
parameters from the same volume, supporting powerful
correlative analyses [91, 92].
We have developed and applied this technology previ-
ously to the structural and photochemical imaging of
human pathological conditions [93–96]. This system has
most recently been applied to cultured glioma cells and
experimental gliomas ex vivo [97–100]. These studies
demonstrated that high microanatomical definition of the
tumor, invasion zone, and normal adjacent brain can be
obtained down to single-cell resolution in unprocessed
tissue blocks. More intriguingly, they can use multiphoton
excitation and four-dimensional microscopy to generate
fluorescence lifetime maps of murine brain anatomy,
experimental glioma tissue, and biopsy specimens of
human glial tumors. In murine brain, cellular and noncel-
lular elements of the normal anatomy were identified.
Distinct excitation profiles and lifetimes of endogenous
fluorophores were identified for specific brain regions.
Intracranial grafts of human glioma cell lines in mouse
brain were used to study the excitation profiles and
fluorescence lifetimes of tumor cells and adjacent host
brain [99]. These studies demonstrated that normal brain
and tumor could be distinguished on the basis of fluores-
cence intensity and fluorescence lifetime profiles. Human
brain specimens and brain tumor biopsies were also
analyzed by multiphoton microscopy, which demonstrated
distinct excitation and lifetime profiles in glioma specimens
and tumor-adjacent brain. This study demonstrates that
multiphoton excitation of autofluorescence can distinguish
tumor tissue and normal brain based on the intensity and
lifetime of fluorescence [99]. Wilson et al. (2009) used
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MPM to visualize the behavior of infiltrating CD8+ T cells
in cerebral cortex by using reticular fiber conduits to move
within the brain [101]. We and others have worked on
technical developments in this technology that may provide
a means for in situ tissue analysis, which might be used to
detect a residual tumor at the resection edge.
We have devised a comprehensive GPS-like tracking
system for stem cell delivery and tracking in vivo with
combination of genetically labeled stem cells and in vivo
imaging technology (Figs. 5, 6, 7, 8, 9). These genetically
labeled stem cells are tagged with constitutive or develop-
mentally regulated viable fluorescent markers for tracking a
transplanted stem cell, in vitro or in vivo by the innovative
GPS-like tracking system [93, 94, 102–104]. In vivo
tracking relies upon nanotechnology coupled with an
optical fiber detector camera probe surgically implanted,
providing continuous circumferential visualization within a
radius of 500 nm.
The miniaturized probes are the most critical components
for the in vivo multiphoton microscope (MPM) imaging
system (Figs. 7, 8, and 9). In the past few years, we have
developed a number of miniaturized probes for OCT and
MPM imaging [93, 94, 104–106]. Figures 7, 8 and 9 show
MEMS-based and needle-based miniature probes. The
fiber-based MPM system offers three advantages over the
current prototype system. The fiber-based femotosecond
pulse (FBFP) source is much more compact and robust than
the Ti:sapphire laser, which is ideal for in vivo imaging
[107, 108]. In addition to the MPM system and probe
development, the fiber based MPM imaging system can be
combined with the optical coherence tomography (OCT)
system to enable simultaneous monitoring and evaluating
of the therapeutic effect of stem cell treatment [107, 109].
Imaging and tracking stem cell distribution in in vitro, ex
vivo and in vivo systems is essential for defining basic stem
cell behavior and for optimizing stem cell therapy. MPM,
which includes multiphoton excited fluorescence and
harmonic generation, has been widely used for biological
imaging with molecular contrast and sensitivity [110–112].
Several groups have shown in ex vivo studies that MPM
can be used to identify the tumor, invasive zone, and
normal adjacent brain with a single-cell resolution [99]. It
has been found that normal and brain tumors can be
distinguished by either fluorescent intensity or lifetimes
profile from endogenous fluorophores. The intrinsic contrast
of MPM imaging technology, combined with fluorescent-
tagged stem cells, would allow imaging, identifying,
tracking and evaluating interactions of tumor cells, and
transplanted stem cells.
To study the in vivo interaction of stem cells with brain
tumors, two fluorescent dyes can be simultaneously infused
intravenously, one of high molecular weight (fluorescein-
labeled dextran, 70 kDa, green fluorescence) for labeling
the stem cells and one of low molecular weight (sulforhod-
Fig. 5 Schematic diagram of the fiber-based MPM system. The double-
clad PCF has a core with a diameter of 16 μm and an inner cladding with
a diameter of 163 μm. Because of the large inner cladding andmultimode
propagation with a large numeric aperture, a much higher collection
efficiency can be achieved in comparison to the conventional single mode
fiber. In addition, the use of a large core double clad PCF minimizes the
pulse broadening due to the nonlinear effect. The scanner and A/D board
are controlled and synchronized by a PC
Pump (976 nm)








Fig. 6 Schematic of the femtosecond fiber laser oscillator. The pump
laser has a central wavelength of 976 nm and maximum power of
20 W. The pump power is delivered to the cladding of the DC gain
fiber through a home-built pump-signal combiner. The Yb-doped
double cladding gain fiber has a core diameter of 10 mm and inner
cladding of 105 mm [116]
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amine B, 559 Da, red fluorescence) for labeling the tumor
cells. A two-photon microscope can be directed through a
cranial window, and obtain separate images of the two dyes
in the cortex. The gains of the two channels may be
adjusted so that the signals coming from within the vessels
are equal. Subtraction of the image of the fluorescein-
dextran from that of the sulforhodamine B gives images in
which the vasculature is invisible and the sulforhodamine B
in the parenchyma will be imaged with high resolution as
described previously [113].
However, current commercial MPM has limited capabil-
ity for in vivo imaging because of the lack of a compact and
flexible miniature probe. We have developed a fiber based
MPM system that is compact and robust for in situ imaging
and tracking stem cell migration, differentiation, and
survival in animal and human subject. There are a number
of obstacles in translating the MPM technology for clinical
applications, including the compact and robustness of the
femtosecond source, efficient excitation light delivery and
signal collection, and probe miniaturization. Our fiber
based MPM addresses these limitations: (1) the develop-
ment of a fiber-based femtosecond-pulse (FBFP) sources as
a stable and compact light source, (2) design and
development of a MPM system that integrates a FBFP
source, a double clad fiber, and a MEMS probe, and (3)
design and development of a miniature scanning probes.
Fiber-Based MPM System Design
The schematic diagram for the endoscopic MPM is shown
in Fig. 5. A short pulse beam generated from the FBFP







Fig. 7 a Schematic of the
MEMS-based miniature probe;
b picture of the MEMS scanner;
c picture of packaged probe
Fig. 8 a Schematic of the
needle-based miniature probe;
b picture of the probe; c picture
of the tip of the probe
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which can negatively pre-chirp the femtosecond pulses in
the pre-chirp unit to compensate for pulse broadening
caused by positive dispersion in the double clad PCF core.
The pre-chirped pulse passes through a dichroic mirror and
is coupled into the double clad PCF. The short pulse light
coupled out from the double clad PCF may be focused on
the tissue through a miniature probe. The fluorescent or
harmonic generation signal can be collected through the
lens in the miniature probe and coupled into both the core
and inner clad modes of the fiber. The collected MPM
signal propagates through the double clad fiber and passes
through the dichroic mirror that removes the excitation
beam. The MPM signal detected by the photomultiply
(PMT) is amplified and digitized.
Design and Development of a Fiber-based Femtosecond-
pulse (FBFP) Source for MPM
One of the key components for MPM is the short pulse
laser. Efficient generation of a nonlinear signal requires
focus of the excitation laser in both space and time.
Therefore, a short pulse source is essential for efficient
MPM signals. Currently, most MPM systems use a Ti:
sapphire laser. The Ti:sapphire laser offers short pulse
width, high power, high repetition rate and wavelength
tunability from 710 nm to 1,000 nm. However, it also has
the disadvantages of being bulky, expensive and not
maintenance-free. Recent advances in the development of
fiber lasers have made an inexpensive, portable and
maintenance-free laser source available.
We have collaborated with Dr. Wise’s group at Cornell
University in developing a fiber laser for in vivo optical
imaging [114, 115]. We have recently developed a compact
fiber laser that meets the requirement of MPM imaging.
The schematic of the fiber laser is shown in Fig. 6 [116].
The pump laser has a central wavelength of 976 nm and a
maximum power of 20 W. The pump power is delivered to
the cladding of the double cladding gain fiber through a
home-built pump-signal combiner. The Yb-doped double
cladding gain fiber (Liekki DC1200-10/125) has a core
diameter of 10 mm and inner cladding of 105 mm. The
fiber laser can generate a 120 fs pulse with an average
power larger than 2 W. The high output power of the fs
pulse of the fiber laser is achieved by the following method.
Fig. 9 a Schematic of the
endoscopic MEMS probe;
b picture of the probe
Fig. 10 MPM images of rat tail tendon (a) and fish scale (b) using
rotational probes. The image is unfolded with the horizontal direction
scanned by a translation stage, and the vertical direction scanned by
the rotational probe. The images are expressed in 8-bit pseudocolor,
and the scale bar is 25 µm [105]
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First, we used a larger core (10 µm) single mode fiber
instead of a 6 µm fiber. The 10 µm diameter core fiber
matches the core diameter of the doped double clad gain
fiber. Hence, the splice loss was reduced. Second, a more
powerful pump laser was used. The pump laser used could
provide a maximum power of 20 W. The desired output
pulse had a pulse width of 120 fs and a wavelength
bandwidth of 40 nm.
Design and Development of MPM Scanning Probes
The miniaturized probes are the most critical components
for an in vivo MPM imaging system. A number of
miniature scanner probes can be developed to meet the
needs of in vivo MPM imaging for tracing stem cell
therapy. In the past few years, Dr. Chen’s group has
developed a number of miniaturized probes for OCT and
MPM imaging [93, 94, 104–106, 117]. MEMS-based and
needle-based miniature probes developed in Dr. Chen’s
laboratory are shown in Figs. 7 and 8.
In addition to the 2-D linear scanner, deep tissue may be
better imaged through a cranial window with a cylindered
geometry. A rotational probe may be optimal to image a
relative large area through the cranial window. We have
developed a rotational probe based on a miniaturized
rotational MEMS motor (Fig. 9) [105, 118, 119]. The
MEMS micromotor is mounted in a backward configura-
tion toward the proximal direction, and a 45° prism is used
to deflect optical light toward the sample. We have built
and tested a prototype device with a motor with a diameter
of 2.2 mm. A GRIN lens with a diameter of 1 mm was used
since it was readily available with 3° cleaved angles.
Imaging was performed by pulling the whole probe with a
linear translational stage while the MEMS motor rotated to
create a 3-D helix scan. Figure 10 shows the preliminary
results of the MPM signal acquired through such a
miniature rotational probe [105].
Signal and Imaging Processing
In addition to the intensity measurement, appropriate
spectral filter can be included in the MPM detection
system so that multiple spectral channel images can be
acquired simultaneously. Furthermore, time-correlated
sing-photon counting can be developed to enable flourescence
lifetime imaging.
To study the in vivo interaction of stem cells with brain
tumors, two fluorescent dyes are simultaneously infused
intravenously, one of high molecular weight (fluorescein-
labeled dextran, 70 kDa, green fluorescence) for labeling the
stem cells and one of low molecular weight (sulforhodamine
B, 559 Da, red fluorescence) for labeling the tumor cells. A
two-photon microscope can be directed through a cranial
window, and obtain separate images of the two dyes in the
cortex. The gains of the two channels are adjusted so that
the signals coming from within the vessels are equal.
Subtraction of the image of the fluorescein-dextran from
that of the sulforhodamine B gives images in which the
vasculature is invisible and the sulforhodamine B in the
parenchyma can be imaged with high resolution as
described previously [113].
Conclusion
(1) We have defined the problems of tracking the migration
and fate of transplanted stem cells. (2) We have also
defined the ideal qualities of a stem cell tracking system for
clinical use. (3) None of the four stem cell tracking
methods fulfill all of the requirements needed for clinical
application at this time. Bioluminescence, despite its high
sensitivity and specificity, proves problematic in animals
bigger than mice. Studies with quantum dots provide
benefits. This labeling system is in its early develop-
mental stage, and further development is necessary if
quantum dots were to be used in clinical function. To
create the optimal in vivo imaging modality, multimodal
markers will provide the benefits of each different
labeling technique. MRI dual-imaging might prove to
be the most favorable combination because MRI is
widely used in hospitals. State of the art confocal and
multiphoton microscopy (MPM) and optical coherence
tomography (OCT) may be integrated to complement
MRI in order to create a biological global positioning
system to track stem cell migration, differentiation, and
survival in vivo.
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